Gamida Cell: Soars on positive data from late-stage cancer therapy study

Hanall Biopharma

10/02/2021 14:22

** Shares of Israel-based biopharma co  GMDA.O  jump 26% to
$14.11 premarket
    ** GMDA on Tuesday aftermarket presented positive full data
from its late-stage study testing omidubicel, its experimental
cell therapy in patients with cancers of the blood and bone
marrow  urn:newsml:reuters.com:*:nBw1Kk2m8a
    ** Co says all three secondary goals demonstrated a
statistically significant improvement among patients treated
with omidubicel vs comparator group; GMDA had reported top-line
results in May showing omidubicel met the study's main goal
    ** Says previously unpublished data from the study relating
to exploratory goals also supports the clinical benefit
demonstrated by the study's main and secondary goals
    ** Piper Sandler raises PT to $25 from $13, H.C. Wainwright
to $27 from $15 
    ** H.C. Wainwright makes GMDA a "top pick" for 2021; expects
submission of rolling marketing application for omidubicel to
the FDA by 2021 end and regulatory approval in 2022
    ** Increases initial market share projections for cell
therapy to 11% vs prior projection of 8%
    ** Stock up 17.9% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))